دورية أكاديمية
Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications.
| العنوان: | Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications. |
|---|---|
| المؤلفون: | Balancin ML; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Baldavira CM; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Prieto TG; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Machado-Rugolo J; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil.; Health Technology Assessment Center (NATS), Clinical Hospital (HCFMB), Medical School of São Paulo State University (UNESP), Botucatu, Brazil., Farhat C; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Assato AK; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Velosa APP; Rheumatology Division of the Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, FMUSP, São Paulo, Brazil., Teodoro WR; Rheumatology Division of the Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, FMUSP, São Paulo, Brazil., Ab'Saber AM; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil., Takagaki TY; Division of Pneumology, Instituto do Coração (Incor), University of São Paulo Medical School (USP), São Paulo, Brazil., Capelozzi VL; Laboratory of Genomics and Histomorphometry, Department of Pathology, University of São Paulo Medical School (USP), São Paulo, Brazil. |
| المصدر: | Frontiers in medicine [Front Med (Lausanne)] 2022 Apr 13; Vol. 9, pp. 871202. Date of Electronic Publication: 2022 Apr 13 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2014]- |
| مستخلص: | Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM histology reveals three major tumor cell populations: epithelioid, sarcomatoid, and biphasic. Using a dissecting approach, we showed that histochemical gradients help us better understand tumor heterogeneity and reconsider its histologic classifications. We also showed that this method to characterize MM tumor cell populations provides a better understanding of the underlying mechanisms for invasion and disease progression. Methods: In a cohort of 87 patients with surgically excised MM, we used hematoxylin and eosin to characterize tumor cell populations and Movat's pentachrome staining to dissect the ECM matrisome. Next, we developed a computerized semi-assisted protocol to quantify and reconstruct the ECM in 3D and examined the clinical association between the matricellular factors and patient outcome. Results: Epithelioid cells had a higher matrix composition of elastin and fibrin, whereas, in the sarcomatoid type, hyaluronic acid and total collagen were most prevalent. The 3D reconstruction exposed the collagen I and III that form channels surrounding the neoplastic cell blocks. The estimated volume of the two collagen fractions was 14% of the total volume, consistent with the median estimated area of total collagen (12.05 mm 2 ) for epithelioid MM. Conclusion: Differential patterns in matricellular phenotypes in MM could be used in translational studies to improve patient outcome. More importantly, our data raise the possibility that cancer cells can use the matrisome for disease expansion and could be effectively targeted by anti-collagen, anti-elastin, and/or anti-hyaluronic acid therapies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Balancin, Baldavira, Prieto, Machado-Rugolo, Farhat, Assato, Velosa, Teodoro, Ab'Saber, Takagaki and Capelozzi.) |
| References: | Br J Cancer. 2010 Nov 9;103(10):1562-70. (PMID: 20959825) Arch Pathol Lab Med. 2018 May;142(5):645-661. (PMID: 29480761) Nat Med. 2011 Mar;17(3):320-9. (PMID: 21383745) J Microsc. 2010 Nov;240(2):122-9. (PMID: 20946378) Science. 2005 Nov 18;310(5751):1139-43. (PMID: 16293750) Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1053-8. (PMID: 25550505) Clin Exp Pharmacol Physiol. 2021 Apr;48(4):543-552. (PMID: 33336399) JCI Insight. 2016 Apr 21;1(5):. (PMID: 27275013) Front Pharmacol. 2016 Mar 04;7:32. (PMID: 26973522) Wound Repair Regen. 2009 Mar-Apr;17(2):153-62. (PMID: 19320882) Glycobiology. 2002 Mar;12(3):37R-42R. (PMID: 11971857) Cancer Res. 1998 Jan 15;58(2):342-7. (PMID: 9443415) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Arch Pathol Lab Med. 2018 Jan;142(1):89-108. (PMID: 28686500) J Thorac Dis. 2015 Jun;7(6):964-80. (PMID: 26150910) Nat Rev Cancer. 2017 Jul 25;17(8):475-488. (PMID: 28740119) Hum Pathol. 2021 Jan;107:58-68. (PMID: 33161029) Histochemistry. 1980 Feb;65(2):131-41. (PMID: 6153646) Magn Reson Imaging. 2012 Nov;30(9):1323-41. (PMID: 22770690) Br J Cancer. 2014 Jul 8;111(1):139-48. (PMID: 24874477) Acta Biomater. 2015 Feb;13:61-7. (PMID: 25462839) Pathology. 2011 Feb;43(2):128-32. (PMID: 21233673) Br J Cancer. 2017 Oct 24;117(9):1341-1348. (PMID: 28817839) Histopathology. 2018 Aug;73(2):327-338. (PMID: 29575153) Nat Commun. 2018 Oct 8;9(1):4144. (PMID: 30297715) Adv Wound Care (New Rochelle). 2016 Mar 1;5(3):119-136. (PMID: 26989578) J Oral Maxillofac Pathol. 2016 Sep-Dec;20(3):405-412. (PMID: 27721605) N Engl J Med. 1999 Sep 2;341(10):738-46. (PMID: 10471461) Adv Drug Deliv Rev. 2007 Nov 10;59(13):1351-65. (PMID: 17804111) Ann Ist Super Sanita. 2015;51(1):52-9. (PMID: 25857384) Matrix Biol. 2017 Jul;60-61:38-56. (PMID: 27932299) Nat Commun. 2019 Mar 22;10(1):1333. (PMID: 30902996) PLoS One. 2012;7(6):e38011. (PMID: 22723842) Int J Cancer. 2008 May 1;122(9):1972-80. (PMID: 18076073) Ann Clin Lab Sci. 1973 May-Jun;3(3):207-11. (PMID: 4122202) Am J Pathol. 1991 Mar;138(3):629-46. (PMID: 2000940) Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879) Eur J Vasc Endovasc Surg. 2002 Nov;24(5):440-4. (PMID: 12435345) Glia. 1999 Jan 15;25(2):179-89. (PMID: 9890632) Cancer Res. 2013 Jul 1;73(13):3833-41. (PMID: 23633490) J Histochem Cytochem. 2014 Oct;62(10):751-8. (PMID: 25023614) APL Bioeng. 2020 May 05;4(2):026105. (PMID: 32455252) Science. 2015 Apr 3;348(6230):74-80. (PMID: 25838376) Br J Ophthalmol. 2014 Feb;98(2):159-61. (PMID: 24288392) IEEE Comput Graph Appl. 2013 Nov-Dec;33(6):26-34. (PMID: 24808128) Cancer Metastasis Rev. 2014 Dec;33(4):1059-79. (PMID: 25324146) Curr Opin Biotechnol. 2003 Oct;14(5):538-46. (PMID: 14580586) Cancer Cell. 2005 Sep;8(3):241-54. (PMID: 16169468) J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42. (PMID: 15838603) Matrix Biol. 2016 Jan;49:10-24. (PMID: 26163349) J Thorac Oncol. 2017 May;12(5):850-859. (PMID: 28257959) Exp Cell Res. 1995 Oct;220(2):312-24. (PMID: 7556439) Cancer Res. 2000 Jan 1;60(1):150-5. (PMID: 10646867) Front Oncol. 2017 Oct 09;7:242. (PMID: 29062810) Arch Pathol. 1972 Aug;94(2):187-91. (PMID: 4114784) Oman Med J. 2021 Mar 31;36(2):e247. (PMID: 33898059) Mod Pathol. 2012 Feb;25(2):260-71. (PMID: 21983936) AMA Arch Pathol. 1955 Sep;60(3):289-95. (PMID: 13248341) Histochem J. 1979 Jul;11(4):447-55. (PMID: 91593) Biomaterials. 2008 Jul;29(20):2969-76. (PMID: 18433861) Bioinformatics. 2017 Aug 01;33(15):2424-2426. (PMID: 28369169) |
| فهرسة مساهمة: | Keywords: Movat's pentachrome stain; Picrosirius; immunohistochemistry; malignant mesothelioma; prognosis |
| تواريخ الأحداث: | Date Created: 20220502 Latest Revision: 20220503 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9043486 |
| DOI: | 10.3389/fmed.2022.871202 |
| PMID: | 35492318 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2022.871202 |